États-Unis · Bourse & Finance · Quartz

Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion

Publié par Quartz · États-Unis il y a 2 h

The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones

Lire l'article complet sur Quartz Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (qz.com)

À lire aussi

American starts letting customers mix cash and miles for tickets

LNG Shipments Through Hormuz Hit Highest Level Since Iran War Began

TechCrunch Disrupt 2026: Blackstone’s Jas Khaira on building the next generation of AI giants

iShares 20+ Year Treasury Bond BuyWrite Strategy ETF declares monthly distribution of $0.2885

Soft Jobs Report Boosts Market Bets Fed Will Skip October Rate Increase

Business Insider

The states where borrowers owe the most in federal student loans, ranked by average balance